Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer

Psoriasis is a chronic relapsing immunoinflammatory dermatosis that is commonly associated with systemic comorbidities. The pathogenic importance of interleukin (IL)-12 and IL-23 is beyond doubt, as well as the involvement of T helper cells (Th)1 and Th17 cells. There is upregulation of the p40 subu...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2012-01, Vol.2012 (2012), p.1-5
Main Authors: Delvenne, Philippe, Humbert, Philippe, Piérard, Gérald E., Hermanns-Lê, Trinh, Quatresooz, Pascale, Piérard-Franchimont, Claudine
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Cytokines
Dermatologie
Dermatology
Disease
Helper cells
Hospitals
Human health sciences
Humans
Immune system
Interleukin-12 - immunology
Interleukin-23 - immunology
Pathogenesis
Psoriasis
Psoriasis - drug therapy
Psoriasis - immunology
Review
Sciences de la santé humaine
Skin diseases
Th17 Cells - immunology
Ustekinumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c544t-95d5b6a4229d4ce6ecc62352e9147a7671b00143fe6d65c85b3d42a6826cadd53
cites cdi_FETCH-LOGICAL-c544t-95d5b6a4229d4ce6ecc62352e9147a7671b00143fe6d65c85b3d42a6826cadd53
container_end_page 5
container_issue 2012
container_start_page 1
container_title BioMed research international
container_volume 2012
creator Delvenne, Philippe
Humbert, Philippe
Piérard, Gérald E.
Hermanns-Lê, Trinh
Quatresooz, Pascale
Piérard-Franchimont, Claudine
description Psoriasis is a chronic relapsing immunoinflammatory dermatosis that is commonly associated with systemic comorbidities. The pathogenic importance of interleukin (IL)-12 and IL-23 is beyond doubt, as well as the involvement of T helper cells (Th)1 and Th17 cells. There is upregulation of the p40 subunit shared by IL-12 and IL-23 and of the IL-23 p19 subunit, but not an increased expression of the IL-12 p35 subunit. This indicates that IL-23 appears more involved than IL-12 in the pathogenesis of psoriatic plaques. Ustekinumab is a fully human monoclonal antibody of the immunoglobulin (Ig) G1 class targeting the p40 subunit common to both IL-12 and IL-23, thus inhibiting both IL-12 and IL-23 receptor-mediated signalling. Ustekinumab is part of the recent biologic therapies active in psoriasis, autoimmune arthritides, and inflammatory bowel diseases.
doi_str_mv 10.1155/2012/147413
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3384985</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1221142330</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-95d5b6a4229d4ce6ecc62352e9147a7671b00143fe6d65c85b3d42a6826cadd53</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhiMEolXpiTuyxAWBQj3jjyQckFZVgZVWooeWq-U43o1LEi920tJ_j3dTVoUL-OKR5pl3PvRm2Uug7wGEOEMKeAa84MCeZMfIgOcSODw9xIwdZacx3tD0SpC0ks-zI8RCcCzK4-zbdRztdzdMva6JG8hl9MHp6CJZ9v00-K0eW9_5zT25c2NLLvptu8_6gYytJVctFPlyhYwsfrr4gSzIZXC9DS-yZ2vdRXv68J9k158urs6_5Kuvn5fni1VuBOdjXolG1FJzxKrhxkprjEQm0FZpJV3IAmpKgbO1lY0UphQ1azhqWaI0umkEO8k-zrrbqe5tY-wwBt2pbRpCh3vltVN_ZgbXqo2_VYyVvCp3AmwW6JzdWOVD7dQt7gv38dRtlDaqtgpRlgrS0QSkqjcPbYP_Mdk4qt5FY7tOD9ZPMWEIwJEx-m-UIsOKFSAT-vov9MZPYUj3S1Sal1aUYaLezZQJPsZg14dtgaqdJ9TOE2r2RKJfPT7Qgf3tgAS8nYHWDY2-c_-nZhNi1_oRjEVFOfsFUhfE7A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1038409032</pqid></control><display><type>article</type><title>Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Delvenne, Philippe ; Humbert, Philippe ; Piérard, Gérald E. ; Hermanns-Lê, Trinh ; Quatresooz, Pascale ; Piérard-Franchimont, Claudine</creator><contributor>Berardesca, Enzo</contributor><creatorcontrib>Delvenne, Philippe ; Humbert, Philippe ; Piérard, Gérald E. ; Hermanns-Lê, Trinh ; Quatresooz, Pascale ; Piérard-Franchimont, Claudine ; Berardesca, Enzo</creatorcontrib><description>Psoriasis is a chronic relapsing immunoinflammatory dermatosis that is commonly associated with systemic comorbidities. The pathogenic importance of interleukin (IL)-12 and IL-23 is beyond doubt, as well as the involvement of T helper cells (Th)1 and Th17 cells. There is upregulation of the p40 subunit shared by IL-12 and IL-23 and of the IL-23 p19 subunit, but not an increased expression of the IL-12 p35 subunit. This indicates that IL-23 appears more involved than IL-12 in the pathogenesis of psoriatic plaques. Ustekinumab is a fully human monoclonal antibody of the immunoglobulin (Ig) G1 class targeting the p40 subunit common to both IL-12 and IL-23, thus inhibiting both IL-12 and IL-23 receptor-mediated signalling. Ustekinumab is part of the recent biologic therapies active in psoriasis, autoimmune arthritides, and inflammatory bowel diseases.</description><identifier>ISSN: 2314-6133</identifier><identifier>ISSN: 1110-7243</identifier><identifier>ISSN: 1110-7251</identifier><identifier>EISSN: 2314-6141</identifier><identifier>EISSN: 1110-7251</identifier><identifier>DOI: 10.1155/2012/147413</identifier><identifier>PMID: 22754278</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Cytokines ; Dermatologie ; Dermatology ; Disease ; Helper cells ; Hospitals ; Human health sciences ; Humans ; Immune system ; Interleukin-12 - immunology ; Interleukin-23 - immunology ; Pathogenesis ; Psoriasis ; Psoriasis - drug therapy ; Psoriasis - immunology ; Review ; Sciences de la santé humaine ; Skin diseases ; Th17 Cells - immunology ; Ustekinumab</subject><ispartof>BioMed research international, 2012-01, Vol.2012 (2012), p.1-5</ispartof><rights>Copyright © 2012 Pascale Quatresooz et al.</rights><rights>Copyright © 2012 Pascale Quatresooz et al. Pascale Quatresooz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2012 Pascale Quatresooz et al. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-95d5b6a4229d4ce6ecc62352e9147a7671b00143fe6d65c85b3d42a6826cadd53</citedby><cites>FETCH-LOGICAL-c544t-95d5b6a4229d4ce6ecc62352e9147a7671b00143fe6d65c85b3d42a6826cadd53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1038409032/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1038409032?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22754278$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Berardesca, Enzo</contributor><creatorcontrib>Delvenne, Philippe</creatorcontrib><creatorcontrib>Humbert, Philippe</creatorcontrib><creatorcontrib>Piérard, Gérald E.</creatorcontrib><creatorcontrib>Hermanns-Lê, Trinh</creatorcontrib><creatorcontrib>Quatresooz, Pascale</creatorcontrib><creatorcontrib>Piérard-Franchimont, Claudine</creatorcontrib><title>Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer</title><title>BioMed research international</title><addtitle>J Biomed Biotechnol</addtitle><description>Psoriasis is a chronic relapsing immunoinflammatory dermatosis that is commonly associated with systemic comorbidities. The pathogenic importance of interleukin (IL)-12 and IL-23 is beyond doubt, as well as the involvement of T helper cells (Th)1 and Th17 cells. There is upregulation of the p40 subunit shared by IL-12 and IL-23 and of the IL-23 p19 subunit, but not an increased expression of the IL-12 p35 subunit. This indicates that IL-23 appears more involved than IL-12 in the pathogenesis of psoriatic plaques. Ustekinumab is a fully human monoclonal antibody of the immunoglobulin (Ig) G1 class targeting the p40 subunit common to both IL-12 and IL-23, thus inhibiting both IL-12 and IL-23 receptor-mediated signalling. Ustekinumab is part of the recent biologic therapies active in psoriasis, autoimmune arthritides, and inflammatory bowel diseases.</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Cytokines</subject><subject>Dermatologie</subject><subject>Dermatology</subject><subject>Disease</subject><subject>Helper cells</subject><subject>Hospitals</subject><subject>Human health sciences</subject><subject>Humans</subject><subject>Immune system</subject><subject>Interleukin-12 - immunology</subject><subject>Interleukin-23 - immunology</subject><subject>Pathogenesis</subject><subject>Psoriasis</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis - immunology</subject><subject>Review</subject><subject>Sciences de la santé humaine</subject><subject>Skin diseases</subject><subject>Th17 Cells - immunology</subject><subject>Ustekinumab</subject><issn>2314-6133</issn><issn>1110-7243</issn><issn>1110-7251</issn><issn>2314-6141</issn><issn>1110-7251</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqNkk1v1DAQhiMEolXpiTuyxAWBQj3jjyQckFZVgZVWooeWq-U43o1LEi920tJ_j3dTVoUL-OKR5pl3PvRm2Uug7wGEOEMKeAa84MCeZMfIgOcSODw9xIwdZacx3tD0SpC0ks-zI8RCcCzK4-zbdRztdzdMva6JG8hl9MHp6CJZ9v00-K0eW9_5zT25c2NLLvptu8_6gYytJVctFPlyhYwsfrr4gSzIZXC9DS-yZ2vdRXv68J9k158urs6_5Kuvn5fni1VuBOdjXolG1FJzxKrhxkprjEQm0FZpJV3IAmpKgbO1lY0UphQ1azhqWaI0umkEO8k-zrrbqe5tY-wwBt2pbRpCh3vltVN_ZgbXqo2_VYyVvCp3AmwW6JzdWOVD7dQt7gv38dRtlDaqtgpRlgrS0QSkqjcPbYP_Mdk4qt5FY7tOD9ZPMWEIwJEx-m-UIsOKFSAT-vov9MZPYUj3S1Sal1aUYaLezZQJPsZg14dtgaqdJ9TOE2r2RKJfPT7Qgf3tgAS8nYHWDY2-c_-nZhNi1_oRjEVFOfsFUhfE7A</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Delvenne, Philippe</creator><creator>Humbert, Philippe</creator><creator>Piérard, Gérald E.</creator><creator>Hermanns-Lê, Trinh</creator><creator>Quatresooz, Pascale</creator><creator>Piérard-Franchimont, Claudine</creator><general>Hindawi Publishing Corporation</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7T5</scope><scope>Q33</scope><scope>5PM</scope></search><sort><creationdate>20120101</creationdate><title>Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer</title><author>Delvenne, Philippe ; Humbert, Philippe ; Piérard, Gérald E. ; Hermanns-Lê, Trinh ; Quatresooz, Pascale ; Piérard-Franchimont, Claudine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-95d5b6a4229d4ce6ecc62352e9147a7671b00143fe6d65c85b3d42a6826cadd53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Cytokines</topic><topic>Dermatologie</topic><topic>Dermatology</topic><topic>Disease</topic><topic>Helper cells</topic><topic>Hospitals</topic><topic>Human health sciences</topic><topic>Humans</topic><topic>Immune system</topic><topic>Interleukin-12 - immunology</topic><topic>Interleukin-23 - immunology</topic><topic>Pathogenesis</topic><topic>Psoriasis</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis - immunology</topic><topic>Review</topic><topic>Sciences de la santé humaine</topic><topic>Skin diseases</topic><topic>Th17 Cells - immunology</topic><topic>Ustekinumab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Delvenne, Philippe</creatorcontrib><creatorcontrib>Humbert, Philippe</creatorcontrib><creatorcontrib>Piérard, Gérald E.</creatorcontrib><creatorcontrib>Hermanns-Lê, Trinh</creatorcontrib><creatorcontrib>Quatresooz, Pascale</creatorcontrib><creatorcontrib>Piérard-Franchimont, Claudine</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Database‎ (1962 - current)</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Middle East &amp; Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Université de Liège - Open Repository and Bibliography (ORBI)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Delvenne, Philippe</au><au>Humbert, Philippe</au><au>Piérard, Gérald E.</au><au>Hermanns-Lê, Trinh</au><au>Quatresooz, Pascale</au><au>Piérard-Franchimont, Claudine</au><au>Berardesca, Enzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer</atitle><jtitle>BioMed research international</jtitle><addtitle>J Biomed Biotechnol</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>2012</volume><issue>2012</issue><spage>1</spage><epage>5</epage><pages>1-5</pages><issn>2314-6133</issn><issn>1110-7243</issn><issn>1110-7251</issn><eissn>2314-6141</eissn><eissn>1110-7251</eissn><abstract>Psoriasis is a chronic relapsing immunoinflammatory dermatosis that is commonly associated with systemic comorbidities. The pathogenic importance of interleukin (IL)-12 and IL-23 is beyond doubt, as well as the involvement of T helper cells (Th)1 and Th17 cells. There is upregulation of the p40 subunit shared by IL-12 and IL-23 and of the IL-23 p19 subunit, but not an increased expression of the IL-12 p35 subunit. This indicates that IL-23 appears more involved than IL-12 in the pathogenesis of psoriatic plaques. Ustekinumab is a fully human monoclonal antibody of the immunoglobulin (Ig) G1 class targeting the p40 subunit common to both IL-12 and IL-23, thus inhibiting both IL-12 and IL-23 receptor-mediated signalling. Ustekinumab is part of the recent biologic therapies active in psoriasis, autoimmune arthritides, and inflammatory bowel diseases.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>22754278</pmid><doi>10.1155/2012/147413</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2314-6133
ispartof BioMed research international, 2012-01, Vol.2012 (2012), p.1-5
issn 2314-6133
1110-7243
1110-7251
2314-6141
1110-7251
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3384985
source Wiley Online Library Open Access; Publicly Available Content (ProQuest); PubMed Central
subjects Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Cytokines
Dermatologie
Dermatology
Disease
Helper cells
Hospitals
Human health sciences
Humans
Immune system
Interleukin-12 - immunology
Interleukin-23 - immunology
Pathogenesis
Psoriasis
Psoriasis - drug therapy
Psoriasis - immunology
Review
Sciences de la santé humaine
Skin diseases
Th17 Cells - immunology
Ustekinumab
title Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T21%3A28%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ustekinumab%20in%20Psoriasis%20Immunopathology%20with%20Emphasis%20on%20the%20Th17-IL23%20Axis:%20A%20Primer&rft.jtitle=BioMed%20research%20international&rft.au=Delvenne,%20Philippe&rft.date=2012-01-01&rft.volume=2012&rft.issue=2012&rft.spage=1&rft.epage=5&rft.pages=1-5&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2012/147413&rft_dat=%3Cproquest_pubme%3E1221142330%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c544t-95d5b6a4229d4ce6ecc62352e9147a7671b00143fe6d65c85b3d42a6826cadd53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1038409032&rft_id=info:pmid/22754278&rfr_iscdi=true